Syngene International Limited (SYNGENE) Q2 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

Syngene International is a Bengaluru-headquartered contract research, development and manufacturing organization (CRDMO) serving pharma, biotech, nutrition and specialty chemical clients across small and large molecules. The Q2 print will speak to whether the Zoetis/Librela offtake gap — sized at nearly $50 million — peaks in H1 as guided, and whether the mid-20s FY27 margin path with H2 margins of 27-30% remains credible after Q1's 12.3%.

Syngene International Limited Q2 Results Date and Time

Per the board meeting intimation dated October 8, 2026, the Board will approve Q2/H1 FY27 results on October 27, 2026. The trading window is shut from October 1 to October 29, 2026.

An analyst call is scheduled for October 28, 2026, per the board meeting intimation. No dial-in details or webcast link were stated in the intimation.

What to expect from Syngene International Limited's Q2 FY27 results

The Q2 FY27 print is the first in-quarter checkpoint against the rebased FY27 guidance of a single-digit revenue decline in rupee terms and mid-20s EBITDA margins, set on July 29, 2026 with Q1's 12.3% margin already known. The Zoetis/Librela offtake gap — guided as most pronounced in Q1 and Q2 FY27 with a contract impact of nearly $50 million — remains the single largest swing factor, and the client's own August 6, 2026 print showed US revenue down 7% citing lower Librela sales alongside a FY2026 guidance cut. External demand signals through the quarter were supportive: FDA novel approvals numbered 47 as of October 20, 2026 versus 46 for all of 2025, 23 biotechs IPO'd in the first three quarters of 2026 nearly triple the eight in all of 2025, and the BIOSECURE Act was enacted as part of the FY2026 National Defense Authorization Act, embedding the China+1 molecule-shift rationale management cites. On costs, the rupee traded near 95.99 per dollar at end-September against 88.69 a year earlier, but one-month forward premia rose from 3.39% to 5.21% over late September, keeping the hedge-loss run-rate (Rs. 50 Cr in Q1 FY27, Rs. 23.3 Cr in Q3 FY26, Rs. 21 Cr in Q4 FY26) a live margin variable. The upcoming call is also the natural deadline for new MD & CEO Siddharth Mittal's promised 'deep diagnosis' of the business and the medium-term visibility deferred at the Q1 call.

Key Things To Watch

Guidance scorecard: FY27 revenue and margin path: Q2 is the first checkpoint against the July 2026 rebased guidance.

• FY27 revenue — single-digit decline in rupee terms — Q2 print is the first in-quarter checkpoint; H1 was guided to degrowth
• FY27 EBITDA margin — mid-20s — Q1 actual was 12.3%; the guided path requires H2 margins of 27-30%, so probe whether the H2 bridge (revenue uptick + cost savings + Q4 seasonality) is intact
• H2 FY27 meaningfully stronger than H1 — watch for evidence on CDMO and discovery order visibility, which management said would improve in H2
• Return to profitable, sustainable growth from FY28 onwards — any reiteration or re-timing; underlying growth ex-single product stated at 'high-single to low-double digit'

Zoetis/Librela offtake and follow-on opportunity

• Quantified Q2 offtake impact against the ~$50 million contract sizing; delivery obligations sit in H2 FY27 and potentially into FY28
• Zoetis expected to share its FY28 forecast by end of the calendar year, with management stating 'we do not expect that it will be zero'
• Whether Lenivia (Zoetis's follow-on molecule to Librela, launched in Canada and the EU on July 15, 2026) creates a follow-on manufacturing opportunity — the question was raised on the Q4 FY26 call without a substantive management response

Bayview operationalization and capitalization update

• Bayview (Baltimore, US) — process and equipment validation complete; management expects it to be 'operationalized later this year' with customer lock-in expected post-operationalization and revenues starting next year
• Bayview will not be capitalized during FY27; the promised capitalization plan update and whether Bayview costs are inside the mid-20s margin guidance remain open items
• Asset turnover normalization for Bangalore and Bayview facilities guided at 3-5 years from the ~$200 million invested over the prior two years

New leadership's promised 'deep diagnosis' and portfolio strategy

• New leadership requested a quarter to conduct a 'deep diagnosis' of the financial numbers before providing better visibility — the Q2 call is the natural deadline for portfolio strategy and medium-term outlook
• Research services client attrition trend after the Q1 disclosure of 'attrition of a few clients' linked to the deliberate pullback from low-margin work
• Whether further termination-benefit/restructuring charges emerge after Rs. 10 Cr (Q1 FY27) and Rs. 25 Cr (Q4 FY26) net-of-tax items

Margin recovery and hedge-loss run-rate

• Operating EBITDA margin recovery from 12.3% in Q1; segment mix versus the two-thirds CRO / one-third CDMO modelling frame
• Forex hedge losses recurred across Q3 FY26 (Rs. 23.3 Cr), Q4 FY26 (Rs. 21 Cr) and Q1 FY27 (Rs. 50 Cr) against rising forward premia
• Utilization commentary for Mangalore, Unit 3 and Bayview; net cash trajectory after the Rs. 259 Cr sequential decline in Q1 FY27, attributed to the customer-advance cycle